Using open science to develop Pediatric Cancer Drugs
Supported by:
19 September 2017
Childhood brain tumours are genetically distinct from adult cancers and are not a focus area for drug development. M4K Pharma is pioneering a novel open science business model to address these unprecedented “high risk” targets for a fraction of the usual cost.
In this webinar, the speakers showcase how collaboration between patient groups, charities, and academia resulted in the development of small molecule inhibitors targeting high-grade diffuse intrinsic pontine glioma (DIPG) that forms in the brainstem and has a median patient survival time of 9-12 months.
The presenters are Alex Bullock, PhD from the Structural Genomics Consortium and Owen Roberts, CEO, M4K Pharma and Nobelex Biotech.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery Processes, Immunology, Screening
Related organisations
Charles River Laboratories
